2.2.0.25falsefalse40305 - Disclosure - BUSINESS SEGMENT INFORMATION (Schedule of Capital Expenditures and Depreciation of Property, Plant and Equipment within the Bio Pharmaceuticals Segment) (Details)truefalseIn Millionsfalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000014272duration2010-01-01T00:00:002010-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Divide<
MeasureSchema>http://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$Duration_1_1_2009_To_12_31_2009http://www.sec.gov/CIK0000014272duration2009-01-01T00:00:002009-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$Duration_1_1_2008_To_12_31_20083http://www.sec.gov/CIK0000014272duration2008-01-01T00:00:002008-12-31T00:00:00Unit1Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0bmy_BusinessSegmentInformationAbstractbmyfalsenadurationBUSINESS SEGMENT INFORMATION [Abstract]falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringBUSINESS SEGMENT INFORMATION [Abstract]falsefalse3false0us-gaap_SegmentReportingInformationExpendituresForAdditionsToLongLivedAssetsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse424000000424falsetruefalsefalsefalse2truefalsefalse634000000634falsetruefalsefalsefalse3truefalsefalse686000000686falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemo
netaryTotal expenditures for additions to long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets of the reportable segment. Must be disclosed if the amount (a) is included in the determination of segment assets reviewed by the chief operating decision maker or (b) is otherwise regularly provided to the chief operating decision maker, even if not included in the determination of segment assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 28
-Subparagraph b
falsefalse4false0us-gaap_SegmentReportingInformationDepreciationExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse380000000380falsetruefalsefalsefalse2truefalsefalse346000000346falsetruefalsefalsefalse3truefalsefalse361000000361falsetruefalsefalsefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of depreciation expense for the reportable segment. Information should be disclosed if the amount (a) is included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) is otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or lossReference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-Paragraph 27
-Subparagraph e
falsefalse33BUSINESS SEGMENT INFORMATION (Schedule of Capital Expenditures and Depreciation of Property, Plant and Equipment within the Bio Pharmaceuticals Segment) (Details) (USD $)MillionsUnKnownUnKnownUnKnownfalsetrue
